The ASX took a hit on tariff fears with markets dropping globally. Gold soared to new highs and eyes turn to the RBA’s rate ...

According to Arizton’s latest research report, the military simulation and training market is growing at a CAGR of 7.85% during 2024-2030. To Know More, Click: ...

Critical Path Institute® and Boston Medical Center published results for six biomarkers that could improve the early and accurate detection of kidney injury, leading to both the development of safer ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Mashable's shopping experts are keeping track of the best deals available at Amazon throughout the Big Spring Sale. (Our ...

Vertex will not advance VX-264 further in clinical trials. Credit: Andrii Yalanskyi via Getty Images. Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell ...

A monthly overview of things you need to know as an architect or aspiring architect.